Ratio Analysis: Unpacking Revance Therapeutics Inc (RVNC)’s Price-to-Cash and Price-to-Free Cash Flow

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $3.99 in the prior trading day, Revance Therapeutics Inc (NASDAQ: RVNC) closed at $3.76, down -5.76%. In other words, the price has decreased by -$5.76 from its previous closing price. On the day, 1.91 million shares were traded. RVNC stock price reached its highest trading level at $4.005 during the session, while it also had its lowest trading level at $3.64.

Ratios:

Our goal is to gain a better understanding of RVNC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 4.12.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.

On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.

Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when Hollander David sold 3,908 shares for $4.17 per share. The transaction valued at 16,296 led to the insider holds 104,945 shares of the business.

Jordan Erica sold 2,392 shares of RVNC for $9,096 on Apr 16 ’24. The Chief Commercial Officer now owns 114,864 shares after completing the transaction at $3.80 per share. On Mar 18 ’24, another insider, Sjuts Dustin S, who serves as the President of the company, sold 9,211 shares for $5.04 each. As a result, the insider received 46,446 and left with 167,550 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 394431520 and an Enterprise Value of 693803968. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.60. Its current Enterprise Value per Revenue stands at 2.7 whereas that against EBITDA is -3.698.

Stock Price History:

Over the past 52 weeks, RVNC has reached a high of $9.74, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is -29.04%, while the 200-Day Moving Average is calculated to be -18.66%.

Shares Statistics:

The stock has traded on average 3.44M shares per day over the past 3-months and 3588620 shares per day over the last 10 days, according to various share statistics. A total of 104.90M shares are outstanding, with a floating share count of 95.70M. Insiders hold about 8.78% of the company’s shares, while institutions hold 79.61% stake in the company. Shares short for RVNC as of 1730332800 were 10004216 with a Short Ratio of 2.91, compared to 1727654400 on 9539780. Therefore, it implies a Short% of Shares Outstanding of 10004216 and a Short% of Float of 10.94.

Most Popular